Skip to main content

Post-IPO Equity Pharmaceutical Companies

Explore 204 pharmaceutical startups that raised post-ipo equity funding. Access verified founder contact information and fundraising data.

Total Companies
204
Total Funding
$4.1B
Avg Funding
$165.3M
Cities
22

Export 204 Post-IPO Equity Pharmaceutical Companies

Get founder emails, funding data, and company details in one CSV

Start Free Trial

Recently Funded Companies

Export
Wayne, United States
$50.0M
raised

Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.

Oct 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Fort Worth, United States
$11.0M
raised

Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases.

Oct 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Hayward, United States
$250.0M
raised

Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.

Oct 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Watertown, United States
$450.0M
raised

Disc Medicine is a biopharmaceutical company that develops therapies for hematologic diseases and rare blood disorders.

Oct 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

New York, United States
$7.2M
raised

OS Therapies is a therapeutics company focused on the identification, development, and commercialization of treatments for osteosarcoma.

Oct 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 204 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Salt Lake City, United States
$200.0M
raised

Recursion Pharmaceuticals is a biotech company that develops a drug discovery platform and pipeline with machine learning.

Oct 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Needham, United States
$250.0M
raised

Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.

Oct 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Boston, United States
$110.0M
raised

Pyxis Oncology is a biotechnology firm that develops antibody therapeutics intended to promote the body's immune response to cancer.

Sep 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Dallas, United States
$4.0M
raised

Lantern Pharma is a clinical stage biopharma company developing precision oncology therapies leveraging A.I., machine learning, and genomics

Sep 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cincinnati, United States
$12.9M
raised

Onconetix is a biotechnology company that focuses on research and development of universal flu vaccines.

Sep 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 204 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Bromma, Sweden
$3.1M
raised

OncoZenge develops better products for the supportive care of cancer patients.

Sep 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Salt Lake City, United States
$4.0M
raised

Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.

Sep 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Toronto, Canada
$50.0M
raised

Helus Pharma is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions.

Sep 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Waltham, United States
$380.0M
raised

Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.

Sep 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

London, United Kingdom
$393K
raised

New treatment for blood diseases, such as leukemia and lymphoma.

Sep 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 204 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
New York, United States
$150.0M
raised

LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Würzburg, Germany
$23.2M
raised

Pentixapharm develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$375.1M
raised

Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Redwood City, United States
$132.0M
raised

Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

San Diego, United States
$632.5M
raised

Erasca is a developer of oncology drugs intended to provide precision oncology options.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 204 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Englewood Cliffs, United States
$11.7M
raised

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Boca Raton, United States
$8.5M
raised

Grid AI delivers innovative energy management solutions for homes, businesses, and industrial campuses.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$15.0M
raised

Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Palo Alto, United States
$1.0B
raised

BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Houston, United States
$3.0M
raised

FibroBiologics is a regenerative medicine company developing an innovative solution for chronic disease treatment using fibroblast cells.

Jun 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Showing 1 to 25 of 204 companies

Ready to Connect with Post-IPO Equity Pharmaceutical Startups?

Get verified founder emails, funding details, and company data for 204 post-ipo equity pharmaceutical companies.

Get Started - Access Contact Information

Join thousands of sales teams, investors, and service providers using VCBacked